Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Nat Prod ; 77(9): 2014-20, 2014 Sep 26.
Artigo em Inglês | MEDLINE | ID: mdl-25226846

RESUMO

The marine dinoflagellate Karenia brevis produces a family of neurotoxins known as brevetoxins. Brevetoxins elicit their effects by binding to and activating voltage-sensitive sodium channels (VSSCs) in cell membranes. K. brevis also produces brevenal, a brevetoxin antagonist, which is able to inhibit and/or negate many of the detrimental effects of brevetoxins. Brevenal binding to VSSCs has yet to be fully characterized, in part due to the difficulty and expense of current techniques. In this study, we have developed a novel fluorescence binding assay for the brevenal binding site. Several fluorescent compounds were conjugated to brevenal to assess their effects on brevenal binding. The assay was validated against the radioligand assay for the brevenal binding site and yielded comparable equilibrium inhibition constants. The fluorescence-based assay was shown to be quicker and far less expensive and did not generate radioactive waste or need facilities for handling radioactive materials. In-depth studies using the brevenal conjugates showed that, while brevenal conjugates do bind to a binding site in the VSSC protein complex, they are not displaced by known VSSC site specific ligands. As such, brevenal elicits its action through a novel mechanism and/or currently unknown receptor site on VSSCs.


Assuntos
Encéfalo/efeitos dos fármacos , Dinoflagellida/química , Éteres/farmacologia , Polímeros/farmacologia , Sinaptossomos/efeitos dos fármacos , Canais de Sódio Disparados por Voltagem/efeitos dos fármacos , Animais , Ligação Competitiva , Fluorescência , Ligantes , Estrutura Molecular , Neurotoxinas/farmacologia , Ratos
2.
Bioorg Med Chem Lett ; 19(20): 5931-5, 2009 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-19736007

RESUMO

Replacement of the phenyl ring in our previous (morpholinomethyl)aniline carboxamide cannabinoid receptor ligands with a pyridine ring led to the discovery of a novel chemical series of CB2 ligands. Compound 3, that is, 2,2-dimethyl-N-(5-methyl-4-(morpholinomethyl)pyridin-2-yl)butanamide was identified as a potent and selective CB2 agonist exhibiting in vivo efficacy after oral administration in a rat model of neuropathic pain.


Assuntos
Aminopiridinas/química , Morfolinas/química , Piridinas/química , Receptor CB2 de Canabinoide/agonistas , Administração Oral , Aminopiridinas/síntese química , Aminopiridinas/farmacologia , Animais , Cães , Humanos , Masculino , Microssomos Hepáticos , Morfolinas/síntese química , Morfolinas/farmacologia , Dor/tratamento farmacológico , Ligação Proteica , Piridinas/síntese química , Piridinas/farmacocinética , Ratos , Ratos Sprague-Dawley , Receptor CB1 de Canabinoide/agonistas , Receptor CB1 de Canabinoide/metabolismo , Receptor CB2 de Canabinoide/metabolismo , Relação Estrutura-Atividade
3.
Bioorg Med Chem Lett ; 19(2): 309-13, 2009 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-19091565

RESUMO

Previous research within our laboratories identified sulfamoyl benzamides as novel cannabinoid receptor ligands. Optimization of the amide linkage led to the reverse amide 40. The compound exhibited robust antiallodynic activity in a rodent pain model when administered intraperitoneally. Efficacy after oral administration was observed only when ABT, a cytochrome P450 suicide inhibitor, was coadministered.


Assuntos
Benzamidas/farmacologia , Receptor CB2 de Canabinoide/efeitos dos fármacos , Animais , Benzamidas/administração & dosagem , Benzamidas/química , Benzamidas/uso terapêutico , Dor/tratamento farmacológico , Roedores
4.
J Med Chem ; 49(25): 7278-89, 2006 Dec 14.
Artigo em Inglês | MEDLINE | ID: mdl-17149858

RESUMO

The series of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines have been widely investigated as opioid receptor antagonists. One of our research goals was to explore the bioactive conformation of the N-phenethyl trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine derivative 3, prototypical mu-opioid antagonist in this series. In this effort, the rotational degrees of freedom of the N-substituent of 3 were limited by incorporation of an ethylene bridge between the piperidine 2- or 6-position of 3 and the benzylic position of the N-phenethyl moiety. The overall modification led to a novel series of fused bicyclic derivatives of the octahydroquinolizine chemical class, conformationally restricted analogue of 3. The constrained analogues 6 and 9 showed high affinity toward the mu-opioid receptor. Compound 6 was found to be a mu-opioid antagonist, whereas the constrained analogue 9 displayed potent mu-agonist activity in vitro. This study provides additional information about the molecular determinants for mu recognition, the structural features affecting ligand binding, and the structure function relationships.


Assuntos
Piperidinas/síntese química , Receptores Opioides mu/antagonistas & inibidores , Animais , Células CHO , Cricetinae , Cricetulus , Cristalografia por Raios X , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Humanos , Ligantes , Modelos Moleculares , Conformação Molecular , Piperidinas/química , Piperidinas/farmacologia , Ensaio Radioligante , Receptores Opioides mu/metabolismo , Estereoisomerismo , Relação Estrutura-Atividade
5.
J Med Chem ; 49(25): 7290-306, 2006 Dec 14.
Artigo em Inglês | MEDLINE | ID: mdl-17149859

RESUMO

To better understand structural requirements for a mu ligand of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class to interact with the mu opioid receptor, we have described in the previous article (Le Bourdonnec, B. et al. J. Med. Chem. 2006, 25, 7278-7289) new, constrained analogues of the N-phenethyl derivative 3. One of the active constrained analogues, compound 4, exhibited subnanomolar mu-opioid receptor affinity (K(i) = 0.62 nM) and potent mu-opioid antagonist activity (IC(50) = 0.54 nM). On the basis of structure 4, a new series of mu-opioid receptor antagonists were designed. In these compounds the octahydroquinolizine template of 4 was replaced by an octahydro-1H-pyrido[1,2-a]pyrazine scaffold. The new derivatives were tested for their binding affinities and in vitro functional activity against the cloned human mu-, delta-, and kappa-opioid receptors. From this study, we identified compound 36, which displays high affinity toward the mu-opioid receptor (K(i) = 0.47 nM), potent mu in vitro antagonist activity (IC(50) = 1.8 nM) and improved binding selectivity profile mu/kappa and mu/delta, when compared to 4.


Assuntos
Pirazinas/síntese química , Piridinas/síntese química , Receptores Opioides mu/antagonistas & inibidores , Animais , Células CHO , Cricetinae , Cricetulus , Cristalografia por Raios X , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Humanos , Ligantes , Estrutura Molecular , Pirazinas/química , Pirazinas/farmacologia , Piridinas/química , Piridinas/farmacologia , Ensaio Radioligante , Receptores Opioides delta/antagonistas & inibidores , Receptores Opioides kappa/antagonistas & inibidores , Relação Estrutura-Atividade
6.
Org Lett ; 6(3): 385-8, 2004 Feb 05.
Artigo em Inglês | MEDLINE | ID: mdl-14748599

RESUMO

[structure: see text] A model system has been developed to study the synergy between aromatic stacking and hydrogen bonding in the binding of a flavin derivative. The results show that the identity of both the hydrogen bonding and pi-stacking units strongly determine the overall receptor affinity for flavin in both the oxidized and radical anion forms.


Assuntos
Mononucleotídeo de Flavina/metabolismo , Flavina-Adenina Dinucleotídeo/metabolismo , Oxirredutases/química , Oxirredutases/metabolismo , Mononucleotídeo de Flavina/química , Flavina-Adenina Dinucleotídeo/química , Ligação de Hidrogênio , Espectroscopia de Ressonância Magnética , Estrutura Molecular , Oxirredução , Xantenos/química , Xantenos/metabolismo
9.
ChemMedChem ; 2(11): 1552-70, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17918759

RESUMO

For thousands of years mu opioid agonists such as morphine have been utilized for their analgesic properties. Today, morphine and related compounds are still used as a first line therapy in the treatment of moderate to severe pain. However, despite the clear benefits of mu agonists in pain management, severe side effects such as dependence and respiratory depression are associated with use of these drugs. To date, there are only two approved mu opioid antagonists for use in the treatment of these adverse effects, that is, naloxone and naltrexone. However, many other clinical and therapeutic areas have been linked to mu opioid receptor antagonism. These include treatment of opioid induced pruritus of the skin, obesity, and Parkinson-induced tardive dyskinesia. Currently there are two compounds, N-methylnaltrexone and alvimopan, under FDA review as possible treatments for opioid induced bowel dysfunction and postoperative ileus. These compounds are of special interest as they are peripherally restricted. This attribute enables treatment of peripheral side effects induced by opioid agonists without reversal of the centrally mediated analgesia of the agonist. In this article we discuss the structural classes of mu opioid antagonists, their potential clinical applications, and review the relevant patents of the last ten years.


Assuntos
Antagonistas de Entorpecentes/farmacologia , Dor/fisiopatologia , Receptores Opioides mu/antagonistas & inibidores , Humanos , Antagonistas de Entorpecentes/efeitos adversos , Antagonistas de Entorpecentes/química , Receptores Opioides mu/fisiologia , Relação Estrutura-Atividade
10.
Bioorg Med Chem Lett ; 16(4): 864-8, 2006 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-16298525

RESUMO

Structure-activity relationships at the 2alpha-position of the piperidine ring of the trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine mu-opioid antagonist series were investigated. This study showed that only small linear alkyl groups (methyl, propyl) are tolerated at the 2alpha-position of the piperidine ring of this series.


Assuntos
Piperidinas/síntese química , Piperidinas/farmacologia , Receptores Opioides mu/antagonistas & inibidores , Cristalografia por Raios X , Modelos Moleculares , Conformação Molecular , Piperidinas/química , Estereoisomerismo , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa